Quaternary ammonium compounds

Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease

Tuesday, May 26, 2020 - 1:30pm

We look forward to collaborating with FDA and utilizing the benefits associated with Fast Track designation to make this important therapy available for patients with IFALD.

Key Points: 
  • We look forward to collaborating with FDA and utilizing the benefits associated with Fast Track designation to make this important therapy available for patients with IFALD.
  • Programs with Fast Track designation may benefit from early and frequent interactions with the FDA over the course of drug development.
  • IV Choline Chloride has been granted Orphan Drug Designation for the treatment of IFALD and prevention of choline deficiency in PN patients.
  • IV Choline Chloride has also been granted Fast Track Designation for the treatment of IFALD.

The L-Carnitine market was valued at US$ 47.1 million in 2018 and is projected to reach US$ 72.7 million by 2027; it is expected to grow at a CAGR of 4.9% from 2019 to 2027

Saturday, May 23, 2020 - 1:20am

It is also approved to treat Carnitine deficiencies in patients at the end stage of renal diseases, undergoing hemodialysis..

Key Points: 
  • It is also approved to treat Carnitine deficiencies in patients at the end stage of renal diseases, undergoing hemodialysis..
  • Besides its uses in human nutrition, L-Carnitine is also used as an additive in animal feed formulations.
  • Ltd; Lonza Group Ltd; Northeast Pharmaceutical Group Co., Ltd; Merck KGaA; and Biosint S.p.A., has bolstered the growth of the L-Carnitine market.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma

Friday, May 1, 2020 - 7:52am

If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.

Key Points: 
  • If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.
  • Under the agreement, Sosei Heptares is entitled to certain development and sales-based milestones, and royalties on net sales upon successful commercialisation of Enerzair Breezhaler.
  • Shinichi Tamura, President and CEO of Sosei Heptares, commented:"The recommendation for the approval of Enerzair Breezhaler is a great step towards it becoming available to the many uncontrolled asthma patients in the European Union.
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma

Friday, May 1, 2020 - 7:48am

If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.

Key Points: 
  • If the EC follows this recommendation and approves Enerzair Breezhaler, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.
  • Under the agreement, Sosei Heptares is entitled to certain development and sales-based milestones, and royalties on net sales upon successful commercialisation of Enerzair Breezhaler.
  • Shinichi Tamura, President and CEO of Sosei Heptares, commented:"The recommendation for the approval of Enerzair Breezhaler is a great step towards it becoming available to the many uncontrolled asthma patients in the European Union.
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.

Europe Choline Chloride Market to 2027 - Regional Analysis and Forecasts by End-Use Industry, and Country

Wednesday, April 22, 2020 - 7:20pm

The multiple application of choline chloride is expected to create a significant opportunity for choline chloride market across the world.

Key Points: 
  • The multiple application of choline chloride is expected to create a significant opportunity for choline chloride market across the world.
  • Based on product, the European choline chloride market is segmented into feed industry, human nutrition, oil and gas industry, and others.The feed industry segment holds the largest share in the European choline chloride market.
  • Moreover, rapid growth in the feed industry across Europe is fuelling the growth of the choline chloride market.
  • Based on region, the European choline chloride market is segmented into Germany, France, Russia, Italy, the UK, and Rest of Europe.Germany holds the largest share of the European choline chloride market, which is followed by France.

Asia Pacific Choline Chloride Market to 2027 - Regional Analysis and Forecasts by End-Use Industry, and Country

Wednesday, April 22, 2020 - 3:10pm

The multiple application of choline chloride is expected to create a significant opportunity for choline chloride market across the world.

Key Points: 
  • The multiple application of choline chloride is expected to create a significant opportunity for choline chloride market across the world.
  • Based on product, the choline chloride market in APAC is segmented into feed industry, human nutrition, oil and gas industry, and others.The feed industry segment holds the largest share of the choline chloride market in APAC.
  • Moreover, rapid growth in the feed industry in APAC region is fuelling the growth of the choline chloride market.
  • Based on country, the choline chloride market in APAC is segmented into Australia, China, India, Japan, South Korea, and Rest of APAC.The China holds the largest share of the choline chloride market in APAC, which is followed by India.

Sesderma Laboratories Communicates the Effectiveness of Lactyferrin Forte Solution in Boosting Immunity

Friday, April 17, 2020 - 10:10am

The company has named this combination as Lactyferrin.

Key Points: 
  • The company has named this combination as Lactyferrin.
  • Lactyferrin can also suppress replication of the virus after the virus enters the cell as in the case of AIDS (Puddu et al, 1998).
  • Since liposome is made of soy lecithin (phosphatidyl choline), LF is biodegradable and biocompatible, which means it is very safe.
  • For more information about Sesderma and Lactyferrin, visit https://www.sesderma.com/es_es/home

Insights on the L-Carnitine Industry to 2025 - by Product, Process, Application & Region - ResearchAndMarkets.com

Wednesday, April 15, 2020 - 2:05am

The Global L-Carnitine Market size is expected to reach $219.2 Million by 2025, rising at a market growth of 4.56% CAGR during the forecast period.

Key Points: 
  • The Global L-Carnitine Market size is expected to reach $219.2 Million by 2025, rising at a market growth of 4.56% CAGR during the forecast period.
  • L-carnitine is a form of amino acid and is the main protein element in the body that is naturally formed by acid to produce energy.
  • Based on Application, the market is segmented into Healthcare Product, Functional Drink, Medicine and Animal Food.
  • Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

Oyster Point Pharma to Present at the Cowen 40th Annual Healthcare Conference

Monday, February 24, 2020 - 1:00pm

To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .

Key Points: 
  • To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .
  • Replays of the webcast will be available on the Oyster Point Pharma website for approximately 30 days following the presentation.
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
  • Oyster Point Pharmas lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

2020 Global L-Carnitine Market, Size, Share, Outlook, Growth Opportunities & Forecast - ResearchAndMarkets.com

Thursday, February 20, 2020 - 10:33am

The "2020 Global L-Carnitine Market, Size, Share, Outlook and Growth Opportunities, Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2020 Global L-Carnitine Market, Size, Share, Outlook and Growth Opportunities, Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The L-Carnitine market is likely to witness a stable growth rate over the forecast period driven by growing demand from emerging markets.
  • Increasing family disposable incomes coupled with strengthening buyer power will support the L-Carnitine market growth between 2020 and 2026.
  • The report 2020 Global L-Carnitine Market, Size, Share, Outlook and Growth Opportunities' is a comprehensive work on the L-Carnitine markets, companies, types, applications, and end-user verticals.